Novartis

Tokai Pharmaceuticals raises $23 million in funding

Tuesday, September 20, 2011 01:45 PM

Tokai Pharmaceuticals, a biopharmaceutical company focused on developing new treatments for prostate cancer, has raised $23 million in a Series D3 financing. The proceeds will be used to support the ongoing clinical development of galeterone (TOK-001), the company's lead drug candidate, which has completed an initial proof-of-concept phase 1 clinical trial for the treatment of patients with castration resistant prostate cancer (CRPC). The financing round included both current investors, Novartis Venture Fund and Apple Tree Partners.

More... »

Novartis' canakinumab to potentially treat childhood arthritis

Monday, September 19, 2011 12:48 PM

Novartis has presented late-stage data showing that canakinumab, recently rejected by US regulators for gout, shows potential as a treatment for patients with the most serious form of childhood arthritis, according to PharmaTimes.

More... »

Roche CEO says diagnostics will maintain its lead in targeted drugs

Thursday, September 1, 2011 02:15 PM

Roche expects a new generation of drugs targeted at specific groups of patients to make up half its portfolio in 10 years, a shift that is pushing the boundaries of modern medicine, according to Reuters.

More... »

Novartis considers IPO in China

Wednesday, July 13, 2011 10:10 AM

Swiss drug maker Novartis is considering a possible initial public offering in China, joining a growing list of multinationals eyeing a listing on Shanghai's planned international board, two people with knowledge of the situation told Reuters.

More... »

Sangamo names Nichol executive vice president of R&D

Monday, July 11, 2011 12:48 PM

Sangamo BioSciences has named Geoffrey M. Nichol executive vice president, R&D. In this newly created position, Dr. Nichol will oversee all of the company's research and clinical development activities and operations.

More... »

Novartis phase III trial meets primary endpoint

Friday, July 8, 2011 12:26 PM

Novartis announced phase III trial results that showed more than one-third of patients taking AfinitorR (everolimus) tablets experienced a 50% or greater reduction in the size of their subependymal giant cell astrocytomas (SEGAs), non-cancerous brain tumors associated with tuberous sclerosis complex (TSC).

More... »

FDA approves Novartis drug to treat pancreatic neuroendocrine tumors

Friday, May 6, 2011 12:34 PM

The FDA has approved the Novartis drug Afinitor(everolimus) for the treatment of advanced pancreatic neuroendocrine tumors. 

More... »

Novartis CEO unveils drug development strategy

Wednesday, May 4, 2011 12:43 PM

During a recent interview with Fortune, Novartis CEO Joe Jimenez explained the company's drug development strategy. He reported that Novartis isn’t targeting blockbuster indications but are more focused on pathways, as reported in Fierce Biotech.

More... »

Sosei, Novartis report NVA237 improves lung function

Tuesday, April 19, 2011 12:31 PM

International biopharmaceutical and drug development company Sosei reports that NVA237, a long-acting muscarinic antagonist (LAMA) being investigated as a once daily treatment for chronic obstructive pulmonary disease (COPD), achieved its primary end point in a phase III study. The drug is licensed to Novartis; the company confirmed results from the first phase III clinical trial with once-daily NVA237 (glycopyrronium bromide) show that it significantly improved lung function while demonstrating a good safety profile in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).

More... »

Report: Some sponsors more prepared to lead the way in personalized medicine than others

Monday, April 18, 2011 08:05 AM

As the pharmaceutical industry’s investment in personalized medicine leads to development of an increasing number of targeted therapies, particularly for cancer patients, some drug sponsors have shown greater commitment and more structure in their approach than others, according to a new report by consulting firm Diaceutics.

More... »